DAPSONE | N207154 | ALMIRALL LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2020-07-22 | Terminated 2021-01-19 | — | |
| D.N.J. | 2020-01-09 | Terminated 2021-03-01 | — | |
| D. Del. | 2019-04-09 | Terminated 2022-05-23 | — | |
| D. Del. | 2017-07-28 | Terminated 2019-03-11 | — | |
| D. Del. | 2017-06-01 | Terminated 2019-03-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lachman Consultant Sevices, Inc.- Citizen Petition FDA-2013-P-0800 · 3 docket documents Lachman Consultant Services, Inc. filed this citizen petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Dapsone Tablets, 50 mg, suitable for submission as an ANDA, with the reference listed drug being Dapsone Tablets USP, 100 mg (ANDA | Other | 2013-07-15 | Withdrawn | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 11273132 | Nov 18, 2033 | — | — | Yes | — | — |